Clinical Trials Browser

Ovarian Neoplasms, Pancreatic Neoplasms

Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Endometrial Neoplasms

Lymphatic Metastasis, Melanoma

Melanoma, Skin Neoplasms

Anatomic Stage IV Breast Cancer AJCC v8

Craniopharyngioma

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Brain Neoplasms, Melanoma

Thyroid Neoplasms

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

Leukemia, Hairy Cell

Brain Neoplasms, Melanoma

Leukemia, Hairy Cell

Melanoma, Neoplasms

Brain Neoplasms, Melanoma, Neoplasm Metastasis

Neurofibroma, Neurofibromatosis 1, Peripheral Nervous System Neoplasms, Neurofibromatoses, Neurofibroma, Plexiform

Breast Neoplasms, Triple Negative Breast Neoplasms

Carcinoma, Non-Small-Cell Lung

Astrocytoma, Glioblastoma, Glioma, Gliosarcoma

Neoplasm Metastasis, Colorectal Neoplasms

Colorectal Neoplasms

Brain Neoplasms, Melanoma

Pancreatic Neoplasms

Colorectal Neoplasms

Melanoma, Hereditary Sensory and Autonomic Neuropathies

Pancreatic Neoplasms

Multiple Myeloma, Recurrence

Brain Neoplasms, Melanoma

Brain Neoplasms, Melanoma

Melanoma, Neoplasms

Noonan Syndrome 5, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Leukemia, Myeloid, Acute, Hematologic Neoplasms

Clinical Trials

Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement

PORTSIDE

Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial)

MEKTOVI® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma

OCEANII

Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma

Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid Cancer

Testing Binimetinib as a Potential Targeted Treatment in Cancers With NRAS Genetic Changes (MATCH-Subprotocol Z1A)

ENCO-BRAF

An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer

Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/Refractory HCL

ENCEFALO

Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma

Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant

EBIN

MK3475-C01

EBRAIN-MEL

NF108-BINI

InCITe

Binimetinib and Hydroxychloroquine in Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer

Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype Melanoma

BRAF

Study of Pembrolizumab, Binimetinib, and Bevacizumab in Patients With Refractory Colorectal Cancer

Binimetinib and Palbociclib or TAS-102 in Treating Patients With KRAS and NRAS Mutant Metastatic or Unresectable Colorectal Cancer

SECOMBIT

BEPCOME-MB

Binimetinib and Encorafenib for the Treatment of Pancreatic Cancer in Patients With a Somatic BRAF V600E Mutation

LOGIC-2

ANCHOR-CRC

A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma

Perfume

GMMG-BIRMA

MEMBRAINS

POLARIS

Study of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation

PREMIUM

SIGNATURE

Intermittent LGX818 and MEK162 in Treating Patients With Metastatic Melanoma Who Have BRAFV600 Mutations